Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
J Appl Toxicol ; 44(2): 216-234, 2024 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-37646119

RESUMEN

Serotonergic psychedelics, such as lysergic acid diethylamide (LSD), psilocybin, dimethyltryptamine (DMT), and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), are currently being investigated for the treatment of psychiatric disorders such as depression and anxiety. Clinical trials with psilocybin and LSD have shown improvement in emotional and psychological scores. Although these drugs are reported to be safe in a controlled environment (such as clinical trials), exposure to low doses of these drugs can result in psychedelic effects, and therefore, occupational safety is an important consideration to prevent adverse effects in the workplace from low daily exposure. This article will discuss the factors involved in the derivation of occupational exposure limits (OELs) and risk assessment of these psychedelic drugs. To support the OEL derivations of psychedelic drugs, information regarding their mechanism of action, adverse effect profiles, pharmacokinetics, clinical effects, and nonclinical toxicity were considered. Additionally, psilocybin and LSD, which are the most extensively researched psychedelic substances, are employed as illustrative examples in case studies. The OELs derived for psilocybin and for LSD are 0.05 and 0.002 µg/m3 , respectively, which indicates that these are highly hazardous compounds, and it is important to take into account suitable safety measures and risk-management strategies in order to minimize workplace exposure.


Asunto(s)
Alucinógenos , Humanos , Alucinógenos/toxicidad , Alucinógenos/uso terapéutico , Psilocibina/toxicidad , Psilocibina/uso terapéutico , Dietilamida del Ácido Lisérgico/toxicidad , Dietilamida del Ácido Lisérgico/uso terapéutico , N,N-Dimetiltriptamina , Medición de Riesgo
2.
Toxicol Mech Methods ; 21(2): 93-6, 2011 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-20507226

RESUMEN

Occupational exposure to active pharmaceutical ingredients in a manufacturing or laboratory environmental can cause unintended health effects in workers handling these compounds. Occupational health professionals in the pharmaceutical industry have responded to this hazard recognition by employing strategies for the risk evaluation and management of potent APIs, otherwise known by the term 'potent compounds'. The purpose of this paper is to provide an overview of the necessary strategy components for preventing occupational exposure to potent compounds.


Asunto(s)
Industria Farmacéutica , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Enfermedades Profesionales/prevención & control , Exposición Profesional/prevención & control , Salud Laboral , Animales , Monitoreo del Ambiente , Humanos , Nivel sin Efectos Adversos Observados , Enfermedades Profesionales/inducido químicamente , Exposición Profesional/efectos adversos , Medición de Riesgo , Especificidad de la Especie
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...